Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 13/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7501094 | 0.91 | CXCR2 (0.44) | CXCR2CNR1CX3CR1ATMLMNA | |
| SCHEMBL27552475 | 0.87 | CXCR2 (0.41) | CXCR2CNR1CX3CR1ATMPOLB | |
| SCHEMBL7542421 | 0.86 | CXCR2 (0.39) | CXCR2CNR1LMNASMN1; SMN2 | |
| SCHEMBL27552190 | 0.86 | CXCR2 (0.41) | CXCR2CNR1CX3CR1ATMPOLB | |
| Trifluoroacetic Acid SCHEMBL7500081 | 0.85 | CXCR2 (0.51) | CXCR2CNR1ATMLMNA | |
| SCHEMBL7118983 | 0.82 | CXCR2 (0.43) | CXCR2CNR1ATMSMN1; SMN2POLB | |
| SCHEMBL2533467 | 0.82 | CXCR2 (0.51) | CXCR2CX3CR1TSHR | |
| SCHEMBL27753417 | 0.82 | CXCR2 (0.59) | CXCR2 | |
| SCHEMBL28748189 | 0.81 | CXCR2 (0.50) | CXCR2CX3CR1TSHR | |
| SCHEMBL7692368 | 0.78 | CXCR2 (0.36) | CXCR2CNR1ATMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030109527-A1 | Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109527-A1 | Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists | CXCL8, CCR8, IL18 | CXCR2 26/4885CNR1 573/4885CX3CR1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.